Drug Profile
KQ 791
Alternative Names: KQ791Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Kaneq Bioscience
- Class Antihyperglycaemics; Insulin sensitisers
- Mechanism of Action Protein tyrosine phosphatase non receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Insulin resistance; Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Insulin-resistance(In volunteers) in Canada (PO, Capsule)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO, Capsule)
- 01 Feb 2016 Kaneq Bioscience completes a phase I trial in Type-2 diabetes in USA (NCT02445911)